Precigen Actobio

Precigen Actobio

Foundation date

03/07/2006

Sector

#Biotechnology - Therapeutics

Subsector

• #Therapeutics - Drug delivery
• #Therapeutics - Peptides
• #Therapeutics - Proteins
• #Therapeutics - Antibodies

Therapeutic areas

• #Digestive system
• #Diseases of the blood and blood-forming organs - immune disorders
• #Endocrine - nutritional and metabolic diseases
• #Neoplasms / cancer / oncology
• #Respiratory system

Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.

We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.

Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.